Search Results
Aug 17, 2026, 08:01 ET Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
STATEN ISLAND, N.Y., Aug. 17, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Aug 14, 2026, 07:01 ET Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Aug 12, 2026, 08:01 ET Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
STATEN ISLAND, N.Y., Aug. 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial
More news about: Acurx Pharmaceuticals, Inc.
Aug 10, 2026, 08:01 ET Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics
STATEN ISLAND, N.Y., Aug. 10, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Jul 14, 2026, 08:00 ET Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
STATEN ISLAND, N.Y., July 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that a
More news about: Acurx Pharmaceuticals, Inc.
Jul 08, 2026, 08:00 ET Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., July 8, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Jun 16, 2026, 08:00 ET Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
STATEN ISLAND, N.Y., June 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial
More news about: Acurx Pharmaceuticals, Inc.
May 12, 2026, 07:01 ET Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
STATEN ISLAND, N.Y., May 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
May 04, 2026, 08:00 ET Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
STATEN ISLAND, N.Y., May 4, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Apr 29, 2026, 08:00 ET Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
STATEN ISLAND, N.Y., April 29, 2026 /PRNewswire/ -- Acurx Pharmaceuticals (Nasdaq: ACXP) (Acurx or the Company), a fully-integrated biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections
More news about: Acurx Pharmaceuticals, Inc.
Apr 20, 2026, 08:00 ET Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., April 20, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Apr 16, 2026, 16:01 ET Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
STATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Apr 16, 2026, 08:00 ET Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
STATEN ISLAND, N.Y., April 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Mar 30, 2026, 07:01 ET Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
STATEN ISLAND, N.Y., March 30, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial
More news about: Acurx Pharmaceuticals, Inc.
Mar 13, 2026, 07:01 ET Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Mar 09, 2026, 08:01 ET Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection
STATEN ISLAND, N.Y., March 9, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Feb 16, 2026, 08:01 ET Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Feb 02, 2026, 08:00 ET USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
STATEN ISLAND, N.Y., Feb. 2, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial
More news about: Acurx Pharmaceuticals, Inc.
Nov 18, 2025, 08:00 ET Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
STATEN ISLAND, N.Y., Nov. 18, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Nov 12, 2025, 07:01 ET Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
STATEN ISLAND, N.Y., Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Nov 10, 2025, 08:00 ET Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
STATEN ISLAND, N.Y., Nov. 10, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial
More news about: Acurx Pharmaceuticals, Inc.
Oct 28, 2025, 08:00 ET Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference
STATEN ISLAND, N.Y., Oct. 28, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), is a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections.
More news about: Acurx Pharmaceuticals, Inc.
Oct 27, 2025, 08:00 ET Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update
STATEN ISLAND, N.Y., Oct. 27, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Oct 09, 2025, 07:30 ET Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors
STATEN ISLAND, N.Y., Oct. 9, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections,
More news about: Acurx Pharmaceuticals, Inc.
Sep 30, 2025, 07:30 ET Acurx Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. difficile Infection
STATEN ISLAND, N.Y., Sept. 30, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company") is a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial
More news about: Acurx Pharmaceuticals, Inc.